Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors within the central anxious procedure, conolidine modulates alternate molecular targets. A Science Developments review identified that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide avail... https://eddies173vht5.vidublog.com/profile